Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

55.8% of patients, for 5mg/day, 20mg/day and 50mg/day, respectively,

compared to 16.7% for placebo.

-- Produced seizure freedom rates of 7.7% for 20 mg-50 mg/day, 8% for

5mg/day and 1.9% for placebo over the treatment period.

Patients in the second study (Abstract 3.218) were randomized to receive 50 mg/day, 150 mg/day, or placebo, administered twice-daily without titration over the 12 week treatment period. The findings for the study's primary endpoint-reduction in weekly seizure frequency over placebo-were not statistically significant. However, an analysis of the study's secondary endpoints demonstrated a clear difference between placebo and the 50 mg/day dose:
-- The median difference versus placebo for the percent reduction from

baseline in seizure frequency per week was 22.5%.

-- There was at least a 50% reduction in weekly seizure frequency from

baseline in 39.6% of patients, compared with 23.1% for placebo.

-- Seizure freedom rates of 9.4% were seen for 50mg/day, compared with

1.9% for placebo.

Retention rates in both studies were high and similar to placebo, with up to 98% of patients in the treatment group completing the studies. The most commonly reported adverse events were nausea, vomiting, fatigue, nasopharyngitis, anorexia, convulsion, dizziness, headache, somnolence, and insomnia. A dose-response relationship was not observed for the majority of adverse events analyzed in the studies.

Phase III clinical trials of brivaracetam as adjunctive therapy in patients with refractory partial onset epilepsy are already underway. Nearly 1,300 epilepsy patients, ages 16-70, will take part in three multicenter, multinational phase III trials. Two randomized, double-blind, placebo- controlled studies are designed to evaluate the efficacy and safety of brivaracetam (5, 20 and 50 mg/day or 20, 50 and 100 mg/day) over 12 weeks in patients with partial onset epilepsy, no
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Luxury Linen purveyor Peacock ... of Dallas to provide logistics and support for one ... Alley has a long history of giving back to the ... of this year's Toy Drive were Whataburger® and 99.5 The ... than the holidays. Providing gifts to children who would otherwise ...
(Date:12/22/2014)... NAPW honors Cheryl A. ... Year. She is recognized with this prestigious distinction for ... organization of professional women in the country, spanning virtually ... Women is a vibrant networking community with over 600,000 ... is passionate and committed to best practices that support ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 Recently, BambooFlooringChina.com, ... durable strand woven bamboo flooring collection , and launched ... 25%. The promotion is valid until Jan. 30, 2015. ... woven bamboo is the hardest bamboo flooring available today; ... resembling that of traditional teak hardwoods. Strand woven bamboo ...
(Date:12/21/2014)... Khanna Vision Institute is pleased to announce ... Helicopters holiday event for underprivileged kids. The highlight was ... by an aspen helicopter pilot. In the cover of ... was visible.(please see accompanying video). Helicopter pilots require great ... many pilots with Pi in eye vision correction. ...
Breaking Medicine News(10 mins):Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...
... ... Ridgway, MD is now performing a new procedure at Baptist Medical Center in Jackson, ... is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, 2010 -- Baptist ...
... families need extra support, study says , FRIDAY, June ... are at increased risk for falling behind in reading ... the American Speech-Language-Hearing Association. , Parents should provide these ... ASHA, which offers the following tips: , Talk ...
... 18 June 2010: There is significant disparity between ,richer, ... to biological treatments for rheumatoid arthritis (RA), according to ... today at EULAR 2010, the Annual Congress of the ... from a separate study show that RA patients report ...
... ... environment, many Adult Learners contact a “For Profit” Online University or ... about returning to school to earn their online degree. What most ... certificates, licenses earned and college level exams successfully completed can all ...
... cost increased, consumption dropped, study found , FRIDAY, June ... soft drinks may reduce consumption and help lower levels ... new study suggests. , Researchers examined what happened during ... Women,s Hospital in Boston increased the price of regular ...
Cached Medicine News:Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2Health News:Country economy is a stronger predictor of therapy initiation 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 3Health News:People May Skip Soft Drinks Rather Than Pay More 2
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... 29 InteKrin Therapeutics presented 6 month Phase 2b clinical ... Selective PPAR-gamma Modulator (SPPARM), from Actos® (pioglitazone), yesterday at the American ... , , ... a novel, non-TZD, selective oral PPAR-gamma modulator (SPPARM) designed to improve ...
... CARLSBAD, Calif. , June 29 Isis ... from seven programs in Isis, broad metabolic disease franchise were ... in Orlando .  These presentations included two oral talks ... in patients with type 2 diabetes and Isis, Phase 1 ...
Cached Medicine Technology:InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone 2InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 2Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 4Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 5Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 6Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 7Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions 8
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: